Eli Casdin - Apr 4, 2022 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Role
Director, 10%+ Owner
Signature
/s/ Eli Casdin
Stock symbol
LAB
Transactions as of
Apr 4, 2022
Transactions value $
$0
Form type
4
Date filed
4/6/2022, 05:54 PM
Previous filing
Mar 3, 2022
Next filing
May 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction LAB Common Stock Award $0 +15.9K $0.00 15.9K Apr 4, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LAB Series B-1 Convertible Preferred Stock Award +128K 128K Apr 4, 2022 Common Stock 37.6M See footnote F2, F3, F4
transaction LAB Stock Option (Right to Buy) Award $0 +23.4K $0.00 23.4K Apr 4, 2022 Common Stock 23.4K $3.99 Direct F5

Explanation of Responses:

Id Content
F1 Represents Restricted Stock Units that vest in four equal annual increments beginning April 4, 2023.
F2 Each share of the Issuer's Series B-1 Convertible Preferred Stock (the "Series B-1 Preferred Stock") is convertible at the option of the Reporting Person at any time into a number of shares of the Issuer's common stock, par value $0.001 per share, equal to the conversion rate, which is initially 294.1176, subject to certain anti-dilution adjustments and limitations on conversion pursuant to the Certificate of Designation for the Series B-1 Preferred Stock.
F3 On April 4, 2022, the Issuer issued the Series B-1 Preferred Stock (i) in exchange for aggregate cash consideration of $112.5 million, pursuant to the Series B-1 Convertible Preferred Stock Purchase Agreement, dated as of January 23, 2022, among the Issuer, Casdin Partners Master Fund, L.P. ("Casdin Master Fund") and Casdin Private Growth Equity Fund II, L.P. ("Casdin Private Growth Fund") and (ii) upon the conversion of $12.5 million aggregate principal amount of term loans, including accrued and unpaid interest, pursuant to the Series B-1 Loan Agreement, dated as of January 23, 2022, among the Issuer, Casdin Master Fund and Casdin Private Growth Fund.
F4 These shares are held by Casdin Master Fund and Casdin Private Growth Fund. Casdin Capital, LLC ("Casdin Capital") is the investment adviser to Casdin Master Fund and Casdin Private Growth Fund. Casdin Partners GP, LLC ("Casdin Partners GP") is the general partner of Casdin Master Fund and Casdin Private Growth Equity Fund II GP, LLC ("Casdin Private Growth GP") is the general partner of Casdin Private Growth Fund. Eli Casdin is the managing member of Casdin Capital, Casdin Partners GP and Casdin Private Growth GP. Each of Casdin Capital, Casdin Partners GP, Casdin Private Growth GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any.
F5 The Option becomes exercisable in four equal annual increments beginning on April 4, 2023.